about
Frontotemporal Lobar Degeneration and MicroRNAsHydrogel-based nanocomposites and mesenchymal stem cells: a promising synergistic strategy for neurodegenerative disorders therapyComparative Magnetic Resonance Imaging and Histopathological Correlates in Two SOD1 Transgenic Mouse Models of Amyotrophic Lateral SclerosisDetection of prion seeding activity in the olfactory mucosa of patients with Fatal Familial InsomniaDisease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseasesMultifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models.Tunable hydrogel-nanoparticles release system for sustained combination therapies in the spinal cord.Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study.In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamolOn-Going Frontal Alpha Rhythms Are Dominant in Passive State and Desynchronize in Active State in Adult Gray Mouse LemursAn N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivoThe neurodegeneration in Alzheimer disease and the prion proteinDifferential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein-specific antibodiesThe Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β OligomersNeuroprotective properties of resveratrol in different neurodegenerative disorders.Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: towards translational challenge models for drug discovery in Alzheimer's disease.Nanovector-mediated drug delivery for spinal cord injury treatment.Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn).ONGOING ELECTROENCEPHALOGRAPHIC ACTIVITY ASSOCIATED WITH CORTICAL AROUSAL IN TRANSGENIC PDAPP MICE (hAPP V717F).Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model.Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples.Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.Role of Glycogen Synthase Kinase-3β in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons.The role of single-nucleotide variants of the energy metabolism-linked genes SIRT3, PPARGC1A and APOE in amyotrophic lateral sclerosis risk.Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease.Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models.A new fluorogenic peptide determines proteasome activity in single cells.Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI).Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70-74-year olds: the InveCe.Ab study.Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis.Impact of 5-HTTLPR polymorphism on alexithymia in alcoholic patients after detoxification treatment.Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors.Melatonin and the Charlson Comorbidity Index (CCI): the Treviso Longeva (Trelong) study.Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples.Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.Body mass index, cognition, disability, APOE genotype, and mortality: the "Treviso Longeva" Study.
P50
Q26768177-CD50C335-8D67-4BA4-BB60-EE26B4076DE5Q27027614-9428CFBE-BC8F-4CDB-90ED-581EFBEE8452Q27303080-1243FA6D-FA42-4B74-BBBC-4CC87E2E72E7Q30844542-F507C165-D7C2-48E1-9DF3-E72A6AD3577BQ34039972-C7D457E9-2F85-4417-AAFD-01352A77030CQ34044084-AE2A45FE-E9B4-47A8-9283-BBE43272D48AQ34345682-363DDE9F-B3A0-4997-8C14-F5EF9240E996Q34641070-FE87D6DD-70D2-4D65-B37E-3DD444CA6360Q34996345-4E0EF916-3E9B-492A-A411-F35FA59B0D02Q35546528-6BD09AF0-2F58-4317-B227-94A6EAA3B1ADQ35855512-EF110B87-808B-40E2-9ABF-5BE2DC16BDD9Q36685236-BA4CA4C2-B6DA-4289-90B4-0ECA65BD5808Q36719033-D8EC1CD2-4A05-48C4-8AD2-55144997100FQ37235627-8282C347-D178-458C-AC91-776963F800E7Q37300268-9B7ACFC4-9679-46F4-9A93-A6ACB315C7BAQ37789699-9D6CA597-C98C-484B-A068-58976BB02C34Q38049711-41C47C2C-AAE4-4F51-8BA9-D0F66EE6B0E0Q38213218-113847E1-9FCC-418F-8EF6-524454D8B825Q38647359-21ACDC47-8893-41B8-A751-6A45192A12F0Q38662925-3E2DDB47-7E46-493A-AF8F-3F1DAE85E989Q38671898-26C73FA0-2BAF-4309-A7E7-BB55F1C218E9Q38783824-2B28041C-C47C-4072-80E3-8FA987DF7674Q38794219-715147B2-71DE-4A3A-9DD8-1A74960CA876Q38818633-7FB11006-F01F-4134-96D5-25688E79FD7DQ38941137-CC271D6D-9C3D-419A-A0E6-EA6A4D22BBFBQ39280294-F44ABAE4-7AF1-4124-B517-3A5F122C352BQ39636393-E4046CE7-B30F-4962-A73D-AC7E60794045Q39649696-3CDE8CC6-C48D-4749-A30A-FDB557E4563DQ40339348-4F057422-8600-4333-AF03-E1ABA9579D05Q40873275-41075211-20B6-426C-A22E-CDED4ECBD137Q41736005-F0FDF6AA-AB7B-4233-BA24-73CE501F3900Q43497178-842DCD0C-1EB4-4B38-A927-7CA7B46C1260Q43799101-E5022B87-00E0-4D45-A36F-5852FD4C4FF0Q43959468-4B745BA1-F1C6-488D-9023-6FDFB477CFE7Q44116778-F949F1D2-DE89-4257-A2BB-9AC5C3E63808Q44801119-4564538C-D545-440F-BBEA-44E7D4C87FC3Q45156606-3FF0429E-4BA4-41D6-BDE5-174BD5CB711FQ45391695-7F2737F2-6567-4B55-B29F-EC88823432C6Q45945144-CDFD147D-3C6A-4FFF-B319-B1E87BDC64D2Q45999932-29D57E2E-3B5E-442E-B78B-2DA42D1578D1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
G Forloni
@en
G Forloni
@nl
type
label
G Forloni
@en
G Forloni
@nl
prefLabel
G Forloni
@en
G Forloni
@nl
P31
P496
0000-0001-5374-3914